Duration of influenza A virus shedding in hospitalized patients and implications for infection control

Infection Control and Hospital Epidemiology

Volumn 28, Issue 9, 2007, Pages 1071-1076

  Leekha, Surbhi ^a   Zitterkopf, Nicole L ^b   Espy, Mark J ^b   Smith, Thomas F ^b   Thompson, Rodney L ^b   Sampathkumar, Priya ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN CELL; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A; MALE; MEDICAL RECORD REVIEW; NONHUMAN; POLYMERASE CHAIN REACTION; STRUCTURED INTERVIEW; THROAT CULTURE; VIRUS DETECTION; VIRUS SHEDDING;

ADULT; AGED; AGED, 80 AND OVER; CELL CULTURE TECHNIQUES; DNA, VIRAL; HOSPITALIZATION; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; TIME FACTORS; VIRUS SHEDDING;

EID: 34548346893     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/520101     Document Type: Article

References (22)

1. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization practices (ACIP). MMWR Recomm Rep 2005; 54(RR-8):1-40.
2. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005; 26:494-500.
3. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352-1355.
4. Englund IA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-1424.
5. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002; 34:E23-E25.
6. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306.
7. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981; 144:433-441.
8. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765.
9. Centers for Disease Control and Prevention. Guidelines and recommendations: infection control guidance for the prevention and control of influenza in acute-care facilities, revision 2/8/07. Available at: http://www.cdc.gov/flu/professionals/infectioncontrol/healthcarefacilities.htm. Accessed March 31, 2007.
10. Tablan OC, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53(RR-3):1-36.
11. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-160.
12. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks IW, Stevenson PG. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997; 159:105-117.
13. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-1169.
14. Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37:427-439.
15. Hebert PL, McBean AM, Kane RL. Explaining trends in hospitalizations for pneumonia and influenza in the elderly. Med Care Res Rev 2005; 62:560-582.
16. Hayden FG, Treanor IJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246.
17. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931-932.
18. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 2003; 9:195-200.
19. Covalciuc KA, Webb KH, Carlson CA. Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods. J Clin Microbiol 1999; 37:3971-3974.
20. Pregliasco F, Mensi C, Camorali L, Anselmi G. Comparison of RT-PCR with other diagnostic assays for rapid detection of influenza viruses. J Med Virol 1998; 56:168-173.
21. Ruest A, Michaud S, Deslandes S, Frost EH. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003; 41:3487-3493.
22. Habib-Bein NF, Beckwith WH III, Mayo D, Landry ML. Comparison of SmartCycler real-time reverse transcription-PCR assay in a public health laboratory with direct immunofluorescence and cell culture assays in a medical center for detection of influenza A virus. J Clin Microbiol 2003; 41:3597-3601.